Mirati Therapeutics Equity 2024

Mirati Therapeutics Aktienanalyse

What does Mirati Therapeutics do?

Mirati Therapeutics Inc is a biotechnology company based in San Diego, California, that focuses on the discovery and development of personalized therapies for cancer. The company was founded in 1995 and originally focused on developing drugs for the treatment of inflammatory diseases. However, in 2012, the company changed its strategy and began to focus on cancer therapies. Mirati Therapeutics' business model is based on the discovery and development of drugs for cancer patients with specific genetic mutations or abnormalities. The company utilizes new insights in cancer genomics to develop targeted therapeutic approaches tailored to the specific needs of cancer patients. The company operates in three different business areas: preclinical research, clinical development, and commercial products. In the preclinical research area, the company focuses on investigating new target candidates and identifying potential drugs for the treatment of cancer. Clinical development involves conducting clinical trials to evaluate the effectiveness and safety of drugs in relation to specific types of cancer. The company also works on marketing and selling commercial products that are already approved on the market and used for the treatment of cancer. One of Mirati Therapeutics' products is the drug Adagrasib, a treatment for patients with advanced non-small cell lung cancer (NSCLC) and specific genetic mutations. Adagrasib aims to inhibit the activity of KRAS, an oncogene that is overexpressed in many types of cancer. The company also has other drugs in the pipeline that are still in preclinical or clinical development. Mirati Therapeutics has partnerships with other companies in the biotech and pharmaceutical industries to advance the discovery and development of new therapies. In 2020, the company announced a strategic collaboration with the pharmaceutical company Amgen to combine Amgen's KRAS inhibitor portfolio with Mirati's and receive milestone payments. The company works closely with the FDA and other regulatory authorities to obtain approval for new drugs and demonstrate the safety and efficacy of its products. The company has made significant progress in the development of personalized cancer therapies in recent years and hopes to be able to help even more patients in the future. In summary, Mirati Therapeutics Inc is an innovative biotechnology company that focuses on the discovery and development of personalized cancer therapies. The company collaborates closely with other industry partners to develop and bring new drugs to the market. Mirati Therapeutics strives to improve the lives of cancer patients and hopes to offer even more innovative therapies in the future. Mirati Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Mirati Therapeutics's Equity

Mirati Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Mirati Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Mirati Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Mirati Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Mirati Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Mirati Therapeutics stock

What is the equity of Mirati Therapeutics this year?

Mirati Therapeutics has equity of 996.5 M USD this year.

What was the equity of Mirati Therapeutics compared to the previous year?

The equity of Mirati Therapeutics has increased/decreased by -28.67% decreased compared to the previous year.

What impact does a high equity have on investors of Mirati Therapeutics?

A high equity is advantageous for investors of Mirati Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Mirati Therapeutics?

A low equity can be a risk for investors of Mirati Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Mirati Therapeutics affect the company?

An increase in equity of Mirati Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Mirati Therapeutics affect the company?

A reduction in equity of Mirati Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Mirati Therapeutics?

Some factors that can affect the equity of Mirati Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Mirati Therapeutics so important for investors?

The equity of Mirati Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Mirati Therapeutics take to change the equity?

To change equity, Mirati Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Mirati Therapeutics pay?

Over the past 12 months, Mirati Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirati Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirati Therapeutics?

The current dividend yield of Mirati Therapeutics is .

When does Mirati Therapeutics pay dividends?

Mirati Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirati Therapeutics?

Mirati Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Mirati Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirati Therapeutics located?

Mirati Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirati Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirati Therapeutics from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Mirati Therapeutics pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Mirati Therapeutics in the year 2023?

In the year 2023, Mirati Therapeutics distributed 0 USD as dividends.

In which currency does Mirati Therapeutics pay out the dividend?

The dividends of Mirati Therapeutics are distributed in USD.